Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

被引：1
|
作者：
Ciccarese, C. [1 ]
Porcari, S. [2 ]
Buti, S. [3 ]
Fornarini, G. [4 ]
Primi, F. [5 ]
Giudice, G. C. [6 ]
Damassi, A. [7 ]
Berrios, J. R. Giron [8 ]
Stumbo, L. [9 ]
Arduini, D. [1 ]
Severino, A. [10 ]
Rondinella, D. [10 ]
Masucci, L. [10 ]
Sanguinetti, M. [10 ]
Gasbarrini, A.
Cammarota, G. [2 ,11 ]
Segata, N. [12 ]
Tortora, G. [13 ]
Ianiro, G. [10 ]
Iacovelli, R. [14 ]
机构：
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCC, Dept Med & Surg Sci UOC Gastroenterol, Rome, Italy
[3] Univ Parma, Univ Hosp Parma, Dept Med & Surg, Med Oncol Unit, Parma, Italy
[4] IRCCS Osped Policlin San Martino, Dept Hematol Oncol, Genoa, Italy
[5] Osped Belcolle ASL Viterbo, Oncol, Viterbo, Italy
[6] Univ Parma, Oncol Med, Parma, Italy
[7] Asl3 Genovese, Med Oncol, Genoa, Italy
[8] Osped Belcolle ASL Viterbo, Med Oncol, Viterbo, Italy
[9] Azienda Osped Univ S Andrea, Med Oncol, Rome, Italy
[10] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Med & Surg Sci UOC Gastroen terol, Rome, Italy
[11] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCC, Dept Internal Med & Gastroenterol, Rome, Italy
[12] Univ Trento, Dipartimento Biol Cellulare Computaz Integrata CI, Cellular Computat & Integrat Biol CIBIO, Povo, Italy
[13] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[14] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2320
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA77
引用
收藏
页码：1264 / 1264
页数：1
相关论文
共 50 条
  • [21] A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
    Kessler, Elizabeth R.
    Callihan, Eryn
    Hu, Junxiao
    Eule, Corbin
    Srivastava, Geetika
    Kemme, Douglas J.
    Iruku, Praveena
    Rana, Vishal
    Moore, James
    Schuster, Steven R.
    Amirault, Mali
    Flaig, Thomas W.
    Lam, Elaine T.
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (06): : 1004 - 1012
  • [22] Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
    Rugo, Hope S.
    Stopeck, Alison T.
    Joy, Anil A.
    Chan, Stephen
    Verma, Shailendra
    Lluch, Anna
    Liau, Katherine F.
    Kim, Sinil
    Bycott, Paul
    Rosbrook, Brad
    Bair, Angel H.
    Soulieres, Denis
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2459 - 2465
  • [23] Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial
    Zhou, Ai-Ping
    Ma, Jianhui
    Bai, Yuxian
    Song, Yan
    Li, Hangzhong
    Xie, Xiaodong
    Ren, Xiu-Bao
    Ye, Dingwei
    Liu, Jiyan
    Luo, Hong
    Bai, Xianzhong
    Qin, Shukui
    Fu, Cheng
    Wang, Jinwan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
    Voss, Martin H.
    Bhatt, Rupal S.
    Vogelzang, Nicholas J.
    Fishman, Mayer
    Alter, Robert S.
    Rini, Brian, I
    Beck, J. Thaddeus
    Joshi, Monika
    Hauke, Ralph
    Atkins, Michael B.
    Burgess, Earle
    Logan, Theodore F.
    Shaffer, David
    Parikh, Rahul
    Moazzam, Nauman
    Zhang, Xiaosha
    Glasser, Chad
    Sherman, Matthew L.
    Plimack, Elizabeth R.
    CANCER, 2019, 125 (14) : 2400 - 2408
  • [25] Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hudes, Gary R.
    Ginsberg, Michelle S.
    Baum, Michael S.
    Harmon, Charles S.
    Kim, Sindy T.
    Chen, Isan
    Redman, Bruce G.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06): : 614 - 618
  • [26] A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
    Gruenwald, Viktor
    Hilser, Thomas
    Meiler, Johannes
    Goebell, Peter J.
    Ivanyi, Philipp
    Strauss, Arne
    Hartmann, Arndt
    Bedke, Jens
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05) : 272 - 280
  • [27] Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients
    Michaelson, M. Dror
    Rini, Brian I.
    Escudier, Bernard J.
    Clark, Joseph
    Redman, Bruce
    Tarazi, Jamal Christo
    Rosbrook, Brad
    Kim, Sinil
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] PHASE III AXIS TRIAL OF AXITINIB VERSUS SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: ASIAN SUBGROUP ANALYSIS
    Uemura, H.
    Ou, Y. -C.
    Lim, H. Y.
    Tomita, Y.
    Ueda, T.
    Menon, H.
    Chung, J.
    Guo, J.
    Tarazi, J.
    Kim, S.
    Naito, S.
    Akaza, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 6 - 6
  • [29] Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC)
    Rini, Brian I.
    Powles, Thomas
    Chen, Mei
    Puhlmann, Markus
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
    Atkins, M. B.
    Plimack, E. R.
    Puzanov, I.
    Fishman, M. N.
    McDermott, D.
    Cho, D. C.
    Vaishampayan, U.
    George, S.
    Olencki, T.
    Tarazi, J.
    Rosbrook, B.
    Fernandez, K.
    Keefe, S.
    Choueiri, T.
    ANNALS OF ONCOLOGY, 2016, 27
12345